Ankyra Therapeutics, Inc.
Clinical trials sponsored by Ankyra Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection targets Hard-to-Treat cancers Results expected Apr 2027 (estimated)
- New combo therapy aims to boost immune response in hard-to-treat lung cancer Results expected Jun 2027 (estimated)
-
New combo therapy aims to boost immune response in hard-to-treat lung cancer
Disease control Recruiting nowThis early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including …
Phase 1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New injection targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…
Phase 1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC